By Fineline Cube 
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Idvynso, a dual-drug single-tablet regimen for adults with HIV-1 infection who are virologically suppressed and meet specific criteria.
Regulatory Approval Details
| Attribute | Detail |
|---|---|
| Indication | Adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA <50 copies/mL) on stable antiretroviral therapy |
| Patient Criteria | No history of virologic failure; no known doravirine-associated resistance mutations |
| Usage | Replacement for current antiretroviral regimen |
| Composition | 100 mg doravirine + 0.25 mg islatravir |
| Approval Date | April 22, 2026 |
Drug Mechanism & Differentiation
- Doravirine: Non-nucleoside reverse transcriptase inhibitor (NNRTI) with well-established efficacy and safety profile
- Islatravir: Next-generation nucleoside reverse transcriptase inhibitor (NRTI) featuring novel translocation inhibition mechanism
- Key Differentiator: Only dual oral regimen that excludes both integrase strand transfer inhibitors (INSTIs) and tenofovir
- Therapeutic Value: Expands diversity of existing oral HIV therapies and provides alternative treatment options for long-term management
Strategic Significance
Idvynso represents a significant advancement in HIV treatment, offering healthcare providers and patients a simplified, two-drug option that maintains viral suppression while avoiding commonly used drug classes. This diversification addresses the need for varied therapeutic approaches in chronic HIV management, particularly for patients seeking to minimize long-term exposure to certain antiretroviral classes.
The approval strengthens Merck’s position in the competitive HIV market and provides an additional tool for personalized treatment strategies in the ongoing effort to optimize long-term outcomes for people living with HIV.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial prospects and market positioning. Actual outcomes may differ based on market adoption, competitive dynamics, and regulatory developments.-Fineline Info & Tech